Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTORNASDAQ:JMACNASDAQ:QTTBNASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$1.47+3.5%$0.86$0.55▼$4.42$105.18M-0.071.09 million shs338,795 shsJMACMaxpro Capital Acquisition$6.82+1.1%$6.07$7.50▼$19.22$145.16M0.0174,040 shs1,078 shsQTTBQ32 Bio$1.70$1.75$1.38▼$53.79$20.74M-0.03199,434 shs57,413 shsZURAZura Bio$1.22-3.2%$1.21$0.97▼$5.07$86.15M-0.12434,394 shs391,454 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology+10.94%+51.34%+59.00%+91.89%+141,999,900.00%JMACMaxpro Capital Acquisition0.00%-0.76%+14.44%+1.72%+2,712.64%QTTBQ32 Bio+1.19%-11.92%+2.41%-7.61%-91.48%ZURAZura Bio-1.56%+6.78%+1.61%+16.67%-67.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTORCitius OncologyN/AN/AN/AN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AQTTBQ32 Bio3.4369 of 5 stars3.14.00.00.04.11.71.3ZURAZura Bio2.7504 of 5 stars3.61.00.00.03.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.00Hold$3.00104.08% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/AQTTBQ32 Bio 2.25Hold$24.711,353.78% UpsideZURAZura Bio 3.13Buy$14.331,074.86% UpsideCurrent Analyst Ratings BreakdownLatest QTTB, CTOR, JMAC, and ZURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.004/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.003/26/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.003/26/2025ZURAZura BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.003/12/2025QTTBQ32 BioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $15.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A($0.22) per shareN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AQTTBQ32 Bio-$6.65M-3.12N/AN/A$22.47 per share0.08ZURAZura BioN/AN/AN/AN/A$1.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius Oncology-$21.15MN/A0.00∞N/AN/A-43.67%-9.74%N/AJMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AQTTBQ32 Bio-$112.96M-$4.94N/AN/AN/AN/A-146.18%-54.49%8/6/2025 (Estimated)ZURAZura Bio-$69.24M-$0.70N/AN/AN/AN/A-37.36%-29.81%8/12/2025 (Estimated)Latest QTTB, CTOR, JMAC, and ZURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/8/2025Q1 2025QTTBQ32 Bio-$1.23-$0.90+$0.33-$0.90N/AN/A5/8/2025Q1 2025ZURAZura Bio-$0.17-$0.19-$0.02-$0.19N/AN/A3/25/2025Q4 2024ZURAZura Bio-$0.17-$0.08+$0.09-$0.08N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.080.340.08JMACMaxpro Capital AcquisitionN/AN/AN/AQTTBQ32 Bio0.616.536.53ZURAZura BioN/A10.3610.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%JMACMaxpro Capital Acquisition73.18%QTTBQ32 Bio31.32%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology4.57%JMACMaxpro Capital Acquisition19.27%QTTBQ32 Bio40.00%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A71.55 million55.17 millionN/AJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableQTTBQ32 Bio3912.20 million10.22 millionN/AZURAZura Bio368.38 million50.86 millionOptionableQTTB, CTOR, JMAC, and ZURA HeadlinesRecent News About These CompaniesCantor Fitzgerald Weighs in on Zura Bio FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comMillennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)June 3, 2025 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by BrokeragesMay 26, 2025 | marketbeat.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comHC Wainwright Issues Positive Estimate for Zura Bio EarningsMay 23, 2025 | marketbeat.comQ1 Earnings Estimate for Zura Bio Issued By HC WainwrightMay 22, 2025 | marketbeat.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025 | businesswire.comZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesMay 9, 2025 | standard-journal.comAfter losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gainApril 24, 2025 | finance.yahoo.comZura Bio price target lowered to $3 from $5 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comZura Bio (ZURA) Gets a Buy from GuggenheimMarch 31, 2025 | markets.businessinsider.comHopeful Week For Insiders Who Bought US$1.01m Of Zura Bio StockMarch 26, 2025 | finance.yahoo.comZura Bio Limited: 2024 Financial Results and Strategic ProgressMarch 26, 2025 | tipranks.comZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesMarch 25, 2025 | businesswire.comZura Bio to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | businesswire.comZURA stock touches 52-week low at $1.44 amid market shiftsFebruary 11, 2025 | msn.comDown -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)January 24, 2025 | zacks.comWe Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business GrowthJanuary 22, 2025 | finance.yahoo.comZura Bio Highlights Strategic Goals and Clinical AdvancesJanuary 13, 2025 | tipranks.comZura Bio initiates Phase II systemic sclerosis treatment trialDecember 25, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong Recoveries3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryTurbulence for Joby Shares: What's Behind the Recent Dip?By Jeffrey Neal Johnson | May 22, 2025View Turbulence for Joby Shares: What's Behind the Recent Dip?QTTB, CTOR, JMAC, and ZURA Company DescriptionsCitius Oncology NASDAQ:CTOR$1.47 +0.05 (+3.52%) As of 04:00 PM EasternCitius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Maxpro Capital Acquisition NASDAQ:JMAC$6.82 +0.08 (+1.11%) As of 06/11/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Q32 Bio NASDAQ:QTTB$1.70 0.00 (0.00%) As of 04:00 PM EasternQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Zura Bio NASDAQ:ZURA$1.22 -0.04 (-3.17%) As of 04:00 PM EasternZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
